Testing zanubrutinib for antiphospholipid syndrome with low platelets
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This Phase 2 study tests zanubrutinib, a medicine for the immune system, to treat antiphospholipid syndrome when it causes very low platelet counts. It looks at safety and whether it can improve blood clotting problems and low platelets when prior steroid treatment didn’t work well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older
- You have been diagnosed with antiphospholipid syndrome
- Your steroid treatment (glucocorticoids) did not work well, could not be kept going, or you couldn’t tolerate it
- Your platelet count is very low (under 30 × 10^9/L)
- Your liver and kidney blood tests are not severely abnormal (ALT, AST, BUN, creatinine under 1.5× the lab’s upper limit)
- You can safely take part in the study (general health not too limited, heart function not too poor) and you can sign consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study looks at zanubrutinib, a new medication, in people with immune thrombocytopenia (ITP) whose low platelet count has lasted more than 3 months and has not responded to prior steroid and other treatments. It may help raise platelets and reduce bleeding risk when other therapies have not worked.
This trial tests an anti-CD38 antibody in people with antiphospholipid syndrome (APS) who have very low platelet counts and haven't improved with steroids or other treatments. The goal is to see if it can safely raise platelet levels.
This trial is testing a combination of targeted drugs, including zanubrutinib, for people newly diagnosed with a fast-growing lymphoma called DLBCL. It is designed for patients with certain risk factors that make their lymphoma more aggressive, and it aims to see if these drug combinations can work better than standard treatments.
This trial tests an oral medication called zanubrutinib to find the best dose for adults newly diagnosed with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, leading to low counts and bleeding risk. It may offer a new treatment option for those who haven't had any prior therapy.
This trial tests a targeted therapy called zanubrutinib for people aged 80 and older with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. It may help control the disease with fewer side effects than standard chemotherapy.
This Phase 2 trial studies zanubrutinib taken after your DLBCL (a type of lymphoma) goes into remission, to help keep it controlled for longer. It focuses on people who have higher-risk features and can safely take this medicine.
Hear when a new Antiphospholipid Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.